Rhumbline Advisers Acquires Shares of 32,138 Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Rhumbline Advisers acquired a new stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 32,138 shares of the company’s stock, valued at approximately $832,000. Rhumbline Advisers owned approximately 0.11% of Dianthus Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $112,000. Virtu Financial LLC acquired a new stake in shares of Dianthus Therapeutics during the 1st quarter worth approximately $390,000. Hussman Strategic Advisors Inc. acquired a new stake in shares of Dianthus Therapeutics during the 1st quarter worth approximately $630,000. StemPoint Capital LP acquired a new stake in shares of Dianthus Therapeutics during the 1st quarter worth approximately $1,304,000. Finally, Bank of New York Mellon Corp raised its position in shares of Dianthus Therapeutics by 860.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock worth $2,095,000 after purchasing an additional 72,509 shares during the period. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH opened at $26.17 on Tuesday. The stock has a fifty day moving average price of $27.92 and a two-hundred day moving average price of $26.17. The firm has a market cap of $768.06 million, a P/E ratio of -4.49 and a beta of 1.85. Dianthus Therapeutics, Inc. has a 1 year low of $6.58 and a 1 year high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). The firm had revenue of $1.86 million for the quarter, compared to the consensus estimate of $0.63 million. Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. On average, research analysts predict that Dianthus Therapeutics, Inc. will post -2.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DNTH has been the topic of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Monday, August 12th. Cantor Fitzgerald started coverage on Dianthus Therapeutics in a research report on Thursday, June 27th. They set an “overweight” rating on the stock. Baird R W raised Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Lifesci Capital raised Dianthus Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Finally, Robert W. Baird started coverage on Dianthus Therapeutics in a report on Friday, July 26th. They issued an “outperform” rating and a $58.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of “Buy” and a consensus price target of $44.71.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.